Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?

Stephanie Shiau, Stephen M. Arpadi, Michael T. Yin

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Purpose of Review: In the era of modern bone-friendly antiretroviral therapy (ART) regimens for people living with HIV (PLWH), this review discusses the research gaps and management concerns that remain for individuals who have already been exposed to ART with negative effects on bone metabolism, especially children and adolescents who have not acquired peak bone mass, and older adults who have additional risk factors for fracture. Recent Findings: Data now support the use of avoidance of TDF and use of bone-friendly regimens that include integrase strand transfer inhibitors in PLWH with increased risk of fracture for either ART initiation or switch. Summary: Despite significant advances in our understanding of ART choice for PLWH with regard to bone health, additional diagnostic tests to determine fracture risk and management strategies beyond ART choice are necessary, especially in vulnerable PLWH populations, such as children and adolescents and older adults.

Original languageEnglish (US)
JournalCurrent HIV/AIDS reports
Issue number1
StatePublished - Feb 1 2020

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases


  • Bone mineral density
  • Fracture
  • Osteoporosis


Dive into the research topics of 'Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?'. Together they form a unique fingerprint.

Cite this